Femoston 1/5 as a preparation continuous combined hormonotherapy in pre- and postmenopausal patients

The paper presents the results of a study of a low-dose drug for continuous HRT - Femoston 1/5. The drug quite effectively eliminates (reduces) psychoemotional and vegetative-vascular symptoms of peri- and postmenopause, eases the course of hypertension, does not affect body weight gain, actually does not cause breakthrough bleeding, growth of myomatous nodes, does not affect the size of the uterus and the thickness of the endometrium (within a year reception). Taking the drug is accompanied by positive dynamics of the level of glycemia, high and low density lipoproteins, the degree of aggregation and intravascular activation of platelets, which improves the state of peripheral blood flow. The presented data allow us to recommend Femoston 1/5 as a means of HRT for postmenopausal and perimenopausal patients with concomitant uterine myoma and endometriosis.